BioSpace News Archive

Business

Harpoon Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

Lead Tri-specific T cell Activating Construct (TriTAC) candidate, HPN424, continues to advance in a Phase 1 clinical trial for the treatment of prostate cancer

March 14, 2019
·
12 min read
Drug Development

Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia

Xeris Pharmaceuticals, Inc. announced that it has now begun dosing patients in a Phase 2 trial with its ready-to-use, room-temperature stable liquid glucagon in patients with Type 1 diabetes who experience episodes of exercise-induced hypoglycemia.

March 14, 2019
·
6 min read
Deals

OTC Markets Lists Securities of Fuse Medical, Inc. as Exempt from Penny Stock Designation

Fuse Medical, Inc. announced that OTC Markets has identified Fuse as “Penny Stock Exempt,” meaning that shares of Fuse’s common stock, par value $0.01 per share, is no longer a “Penny Stock” as defined in Rule 3a51-1, promulgated under the Securities Exchange Act of 1934, as amended.

March 14, 2019
·
3 min read
Business

SCYNEXIS Reports Full Year 2018 Financial Results and Provides Company Update

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the year ended December 31, 2018, and provided an update on recent operational and clinical developments

March 14, 2019
·
13 min read
USA Patent Granted for Recce’s Antibiotics

Recce Pharmaceuticals Ltd (ASX:RCE) (Recce or the Company), the Company developing a new class of broad spectrum synthetic antibiotics, today announced the US Patents and Trademarks Office had Granted 23 claims for patent US 10,226,482 B2, ‘Copolymer and Method for Treatment of Bacterial Infection’.

March 14, 2019
·
1 min read
Drug Development

Imugene Announces First Patient Dosed in the Open-Label Phase 2 Study with HER-Vaxx Cancer Vaccine for Advanced Gastric Cancer

Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced dosing of the first patient in an open-label, randomised multi-centre Phase 2 study with its HER-Vaxx (IMU-131) cancer vaccine for the treatment of HER-2 positive gastric cancer patients.

March 14, 2019
·
3 min read
Deals

Protech Home Medical Engages Oak Hill Financial Inc. to Provide Investor Relations Services

Protech Home Medical Corp. is pleased to announce that it has retained Oak Hill Financial Inc. to provide investor relations services to the Company in compliance with regulatory guidelines.

March 14, 2019
·
5 min read
Deals

Bionano Genomics Enters Into Debt and Equity Financing Agreements Totaling $41.5 Million in Commitments

Bionano Genomics, Inc. announced it has entered into financing agreements totaling $41.5 million in debt and equity commitments from affiliates of Innovatus Capital Partners, LLC, East West Bank and Aspire Capital Fund, LLC.

March 14, 2019
·
8 min read
Biotech Beach

North America’s Fastest Video Gamers Start Speedrunning Marathon at Direct Relief

More than 100 of the fastest video game players in North America gather here starting for three days of non-stop action at the headquarters of the humanitarian medical aid organization Direct Relief.

March 14, 2019
·
1 min read
BioCapital

Versant Health Introduces New Corporate Vision

When Davis Vision and Superior Vision combined to become Versant Health in November 2017, its leadership created a new vision: To become the most trusted managed eye health and vision plan for members, clients, brokers, and providers in the industry.

March 14, 2019
·
2 min read